Bayer's Two-Faced Legal Strategy: Defending Roundup While Playing Offense on mRNA Patents
Published on 08/01/2026 at 19:11 | Redaktion boerse-global.de
The stock market has a short memory for pain, and Bayer's shareholders are the latest beneficiaries. Anyone who bought the shares twelve months ago is sitting on a 78.24 percent gain; those who timed the August trough are up 93.23 percent. Those are not the numbers of a conventional turnaround. They are the numbers of a market radically repricing a company whose defining risk has suddenly shrunk.
That risk, of course, is glyphosate — the legal albatross that has followed Bayer since its ill-fated Monsanto acquisition. For years, the company was the hunted, not the hunter, its valuation hostage to an endless parade of American courtrooms. But the dynamic has shifted in two directions at once: the defense is winning its biggest case, and the offense has finally taken the field.
A Supreme Court Win That Rewrote the Math
The pivotal moment came in June, when the US Supreme Court ruled in Monsanto v. Durnell that Bayer cannot be sued under state laws for alleged failures to warn about cancer risks linked to Roundup. Federal approval requirements, the justices held, preempt state-level claims. The decision stripped the legal foundation from an entire wave of pending lawsuits.
The market's response was immediate and violent: a single-day jump of roughly 17 percent. For a company long traded as a walking litigation risk, it was less a good news day than a wholesale revaluation of the entire enterprise. That helps explain why the stock's 30-day volatility sits at an extreme 61.62 percent. Bayer is not a conventional value stock with steady cash flows; it is a bet on the outcome of a legal saga that has dragged on for over a decade.
Should investors sell immediately? Or is it worth buying Bayer?
The Settlement That Isn't Signed Yet
The next test is already on the calendar. Bayer is negotiating a multibillion-dollar class settlement intended to resolve most of the remaining Roundup claims. Plaintiff attorneys have recently pushed to move the proceedings from Missouri to California — a venue shift that could materially alter the negotiating balance. Bayer expects Missouri to remain the jurisdiction, but no final decision has been made.
That unresolved question explains the recent sideways drift. The stock trades roughly ten percent below its 52-week high of 53.86 euros, reached in early July and never regained since. Whether a single Supreme Court ruling can permanently bury a decade-long legal risk now hinges on a far less dramatic question: which courtroom will oversee the final settlement talks.
From Defendant to Plaintiff
Meanwhile, Bayer has quietly flipped the script. The company is now suing Pfizer and Moderna over mRNA optimization technologies originally developed at Monsanto, seeking a slice of the global vaccine infrastructure. It is a symbolic shift as much as a financial one — the former defendant asserting its own patent claims in American courts.
The offensive extends beyond litigation. Bayer has filed for regulatory approval in China for Kerendia, a treatment for non-diabetic chronic kidney disease. With up to 15 percent of Chinese adults affected by some form of CKD, according to the company, the filing is a calculated bet on a mass-market problem in the world's second-largest economy. In agriculture, meanwhile, the company is pushing "Pack MD Diag+," a product combining herbicides with qPCR-based diagnostic tools for use directly in the field — selling data and efficiency rather than mere chemistry.
Three fronts, one common thread: Bayer is no longer waiting for its legal past to resolve before building its future.
Bayer at a turning point? This analysis reveals what investors need to know now.
What the Charts Say
The market has already embraced the shift. The shares trade 23.69 percent above their 200-day moving average — a wide gap for a DAX heavyweight with a market capitalization near 48 billion euros, suggesting much of the recent gains are young. The RSI of 59.5 signals neither overbought nor oversold conditions, but rather a consolidation phase. Last week's 5.48 percent gain notwithstanding, the technical picture points to a market catching its breath.
The real test comes on Tuesday, August 4, when Bayer releases its first-half results. They will show whether CEO Bill Anderson's restructuring pace matches investor expectations — or whether the share price has already run ahead of the fundamentals. The charts and the balance sheet tell only half the story at Bayer. The other half plays out in American courtrooms, and the next decisive scene is still unwritten.
Ad
Bayer Stock: New Analysis - 1 August
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
